Market closed

QIAGEN/$QGEN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About QIAGEN

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Ticker

$QGEN

Sector

Health Care

Trading on

NYSE

Industry

Life Sciences Tools & Services

Headquarters

Venlo, Netherlands

Employees

5,800

Website

www.qiagen.com

QIAGEN Metrics

BasicAdvanced

$10B

110.95 $0.41

0.40 -

Price and volume

Market cap

$10B

Beta

0.4

52-week high

$47.44

52-week low

$39.03

Average daily volume

780K

Financial strength

Current ratio

2.175

Quick ratio

1.636

Long term debt to equity

38.657

Total debt to equity

57.024

Interest coverage (TTM)

10.46%

Management effectiveness

Return on assets (TTM)

4.89%

Return on equity (TTM)

2.57%

Valuation

Price to earnings (TTM)

110.95

Price to revenue (TTM)

5.161

Price to book

2.9

Price to tangible book (TTM)

14.34

Price to free cash flow (TTM)

22.077

Growth

Revenue change (TTM)

0.54%

Earnings per share change (TTM)

-80.93%

3-year revenue growth (CAGR)

-4.26%

3-year earnings per share growth (CAGR)

-32.78%

What the Analysts think about QIAGEN

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for QIAGEN stock.

QIAGEN Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

QIAGEN Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

QIAGEN News

AllArticlesVideos

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

Business Wire·3 days ago

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

Business Wire·5 days ago

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

Business Wire·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $QGEN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for QIAGEN stock?

QIAGEN (QGEN) has a market cap of $10B as of January 15, 2025.

What is the P/E ratio for QIAGEN stock?

The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 110.95 as of January 15, 2025.

Does QIAGEN stock pay dividends?

No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next QIAGEN dividend payment date?

QIAGEN (QGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for QIAGEN?

QIAGEN (QGEN) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.